PMID- 20079230
OWN - NLM
STAT- MEDLINE
DCOM- 20100506
LR  - 20140226
IS  - 0578-1426 (Print)
IS  - 0578-1426 (Linking)
VI  - 48
IP  - 10
DP  - 2009 Oct
TI  - [Secondary prophylaxis of invasive fungal infection in haematopoietic stem cell 
      recipients].
PG  - 853-6
AB  - OBJECTIVE: To investigate the efficacy and safety of secondary anti-fungal 
      prophylaxis (SAP) in haematopoietic stem cell recipients who had a history of 
      antecedent invasive fungal infection (IFI). METHODS: The patients with 
      hematological diseases, who were scheduled to undergo haematopoietic stem cell 
      transplantation (HSCT) in our unit from April 2005 to July 2008, received our 
      routine conditioning regimen. Patients, who had a history of antecedent IFI, were 
      given SAP from the start of conditioning chemotherapy until the end of the 
      at-risk period. We chose the effective antifungal drug that was used for 
      antecedent IFI as the secondary prophylaxis drug. RESULTS: There were 26 patients 
      at entry. Six patients had probably adverse events (AEs) related to the secondary 
      prophylaxis drug during the prophylactic process and the secondary prophylaxis 
      terminated in two patients because of AEs. The remaining patients received SAP 
      for a medium of 75 days (range 10 - 212 days). Relapsing IFI occurred in four 
      patients during SAP and in one after SAP. The rate of relapsing IFI was 19.2% 
      (5/26). The median time of relapsing IFI was day 42 (range, 1 - 146). The 
      mortality rate among relapsed patients was 60.0% (3/5). No risk factors that 
      might be associated with IFI was identified by logistic regression model. 
      CONCLUSION: Prior IFI is not an absolute contraindication for HSCT. Secondary 
      antifungal prophylaxis can reduce the risk of recurrent infection in patients 
      with prior IFI, but its schedule and time of therapy need further study.
FAU - Xu, Lan-ping
AU  - Xu LP
AD  - Peking University Institute of Hematology, Beijing 100044, China.
FAU - Tang, Fei-fei
AU  - Tang FF
FAU - Liu, Dai-hong
AU  - Liu DH
FAU - Liu, Kai-yan
AU  - Liu KY
FAU - Chen, Huan
AU  - Chen H
FAU - Chen, Yu-hong
AU  - Chen YH
FAU - Huang, Xiao-jun
AU  - Huang XJ
LA  - chi
PT  - English Abstract
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - China
TA  - Zhonghua Nei Ke Za Zhi
JT  - Zhonghua nei ke za zhi
JID - 16210490R
RN  - 0 (Antifungal Agents)
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Antifungal Agents/*therapeutic use
MH  - Child
MH  - Female
MH  - Fungi
MH  - *Hematopoietic Stem Cell Transplantation
MH  - Humans
MH  - Leukemia/microbiology/*therapy
MH  - Male
MH  - Middle Aged
MH  - Mycoses/*prevention & control
MH  - Secondary Prevention
MH  - Young Adult
EDAT- 2010/01/19 06:00
MHDA- 2010/05/07 06:00
CRDT- 2010/01/19 06:00
PHST- 2010/01/19 06:00 [entrez]
PHST- 2010/01/19 06:00 [pubmed]
PHST- 2010/05/07 06:00 [medline]
PST - ppublish
SO  - Zhonghua Nei Ke Za Zhi. 2009 Oct;48(10):853-6.